Teva Pharmaceutical Industries Ltd. (NYSE: Tifa;; level: Tiva) The reports season of Israeli companies were opened by publishing the financial results in the fourth and full year 2024.
In the fourth quarter, the company reported revenues of $ 4.2 billion and NON-GAAP per share of $ 0.71, higher than analysts’ expectations. In the full year, revenues amounted to 2024 $ 16.5 billion, at the upper end from 16.1-16.5 billion dollars, and 4.4 % above 2023 revenues. The profits of non-accounting principles generally accepted for the share in 2024 amounted to $ 2.49 (the company’s instructions were $ 2.40-2.50). However, the company’s share price has opened almost 10 % on the New York Stock Exchange due to disappointing expectations 2025.
TEVA also provided instructions in 2025 for the first time. The company expects 2025 revenues from 16.8-17.4 billion dollars, which represents the annual growth of 3.6 % and uninterrupted profits generally accepted for the share of $ 2.35-2.65. Analysts of the annual revenue of the annual revenue of $ 17.1 billion and profits other than the generally accepted accounting principles per share of $ 2.78, so that profit instructions are less than expectations.
“2024 was a transformative year for TeVA, which led to a second year of growth respectively, driven by our public products and main innovative products. With a focus on the strict implementation of our axis on the growth strategy throughout the year, we continued to achieve features Important in each of its four pillars, including overcoming expectations for our main innovative products, developing our mass drugs in all sectors, and speeding up our innovative pipeline in the early stage, including the positive results of the 2B phase of Duvakitug (Anti-TL1A) origins.
He added, “In 2025, we expect more progress in our main innovative growth drivers, with our complex drugs and our complex works, with the support of the launch of new products. We are also excited to apply for the third -stage experiences for Duvakitug (Anti) -TL1A (Assets.
In general, 2024 was a successful year for Tiva. The share price increased by 111 % during the year, giving it a $ 25 billion roof, making it the most Israeli company. The stock price has been strengthened by the positive results of Duvakitug, to treat Crohn’s disease, which develops with Sanofi.
It was published by Globes, Israel Business News – En.globes.co.il – on January 29, 2025.
© Copy Publish Publisher Itonut (1983) Ltd. , 2025.
Comments are closed, but trackbacks and pingbacks are open.